Biogen China: Together in SMA – back to school

Biogen, a pharmaceutical company, collaborated with a panel of professionals to create a valuable guidebook in China to challenge the stereotype that surviving is the only purpose for those with Spinal muscular atrophy (SMA).


Spinal muscular atrophy (SMA) is a rare and severe neuromuscular disorder. It is a leading genetic cause of mortality in infants under the age of two. No medication was available until the first disease modifying treatment SPINRAZA was developed in 2016. The drug was approved in China in 2019 and was included in the National Reimbursement Drug List (NRDL) at the end of 2021.

This move has improved access to and availability of the drug, resulting in a significant rise in the treatment rate. China became the No.1 market for SPINRAZA four months after the NRDL inclusion.

But as...

Not a subscriber?

Schedule your live demo with our team today

WARC helps you to plan, create and deliver more effective marketing

  • Prove your case and back-up your idea

  • Get expert guidance on strategic challenges

  • Tackle current and emerging marketing themes

We’re long-term subscribers to WARC and it’s a tool we use extensively. We use it to source case studies and best practice for the purposes of internal training, as well as for putting persuasive cases to clients. In compiling a recent case for long-term, sustained investment in brand, we were able to support key marketing principles with numerous case studies sourced from WARC. It helped bring what could have been a relatively dry deck to life with recognisable brand successes from across a broad number of categories. It’s incredibly efficient to have such a wealth of insight in one place.

Insights Team
Bray Leino

You’re in good company

We work with 80% of Forbes' most valuable brands* and 80% of the world's top top-of-the-class agencies.

* Top 10 brands